NasdaqGM:POMHealthcare
Pomdoctor (POM) Losses Persist as Price-to-Sales Premium Tests Bullish Scaling Narrative
Pomdoctor (POM) opened H1 2025 with revenue of CNY 192.4 million and basic EPS of CNY -1.49, while the latest trailing twelve month figures show revenue of CNY 342.6 million and EPS of CNY -3.79. The company has seen revenue move from CNY 177.0 million in H2 2023 to CNY 192.4 million in H2 2024, with net income excluding extra items shifting from CNY -71.3 million to CNY -76.6 million over the same period, setting up a story where investors are weighing top line momentum against still...